Anavex Life Sciences Corp. (AVXL)
| Market Cap | 282.65M -65.4% |
| Revenue (ttm) | n/a |
| Net Income | -39.95M |
| EPS | -0.46 |
| Shares Out | 92.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 795,270 |
| Open | 3.000 |
| Previous Close | 3.040 |
| Day's Range | 2.985 - 3.120 |
| 52-Week Range | 2.610 - 13.990 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 22.00 (+621.31%) |
| Earnings Date | May 12, 2026 |
About AVXL
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price target is $22.0, which is an increase of 621.31% from the latest price.
News
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Provides Comprehensive Regulatory Update
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
This decision follows feedback from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which indicated it would not issue a positive opinion at this time.
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI 1 control group af...
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease
Findings underpin potential of Anavex' lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration Findings underpin potential of Anavex' lead candi...
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Park...
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 am Eastern Time
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET Webcast and Conference Call To be Held Monday, February 9, 2026, 8:30 am ET
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new...
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Dec. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Scien...
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Company to host a webcast t oday at 8:30 a.m. Eastern Time
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatment...
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease
Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW YORK...
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group
ADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'
Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” Presentation title: “Advancing Alzheimer's Disease Care: Convenience for Bot...
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults